You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

~ Buy the AKYNZEO (netupitant; palonosetron hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

akynzeo Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Akynzeo patents expire, and when can generic versions of Akynzeo launch?

Akynzeo is a drug marketed by Helsinn Hlthcare and is included in two NDAs. There are twenty-one patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eighty-five patent family members in fifty-one countries.

The generic ingredient in AKYNZEO is fosnetupitant chloride hydrochloride; palonosetron hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the fosnetupitant chloride hydrochloride; palonosetron hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Akynzeo

Akynzeo was eligible for patent challenges on April 19, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 25, 2035. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for akynzeo?
  • What are the global sales for akynzeo?
  • What is Average Wholesale Price for akynzeo?
Summary for akynzeo
Drug patent expirations by year for akynzeo
Drug Prices for akynzeo

See drug prices for akynzeo

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for akynzeo
Generic Entry Dates for akynzeo*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL
Generic Entry Dates for akynzeo*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for akynzeo

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Simon Williamson ClinicPhase 2
Helsinn Healthcare SAPhase 2
HK inno.N CorporationPhase 1

See all akynzeo clinical trials

Paragraph IV (Patent) Challenges for AKYNZEO
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
AKYNZEO Solution in SDV fosnetupitant chloride hydrochloride; palonosetron hydrochloride 235 mg/0.25 mg per 20 mL 210493 1 2022-04-19

US Patents and Regulatory Information for akynzeo

akynzeo is protected by twenty-three US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of akynzeo is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting akynzeo

Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-to- lyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnet- upitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY

Crystalline forms of an NK-1 antagonist
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Physiologically balanced injectable formulations of fosnetupitant
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Crystalline forms of an NK-1 antagonist
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Substituted piperaziniums for the treatment of emesis
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compositions and methods for treating centrally mediated nausea and vomiting
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY

Compositions and methods for treating centrally mediated nausea and vomiting
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY

Crystalline forms of an NK-1 antagonist
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING EMESIS


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING EMESIS

Substituted 4-phenyl pyridines having anti-emetic effect
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compositions and methods for treating centrally mediated nausea and vomiting
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY

Methods of treating emesis
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY

Compositions and methods for treating centrally mediated nausea and vomiting
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compositions and methods for treating centrally mediated nausea and vomiting
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY

Compositions and methods for treating centrally mediated nausea and vomiting
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY

Compositions and methods for treating centrally mediated nausea and vomiting
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY

4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tol- yl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY

Substituted piperaziniums for the treatment of emesis
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compositions and methods for treating centrally mediated nausea and vomiting
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY

Crystalline forms of an NK-1 antagonist
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Helsinn Hlthcare AKYNZEO fosnetupitant chloride hydrochloride; palonosetron hydrochloride SOLUTION;INTRAVENOUS 210493-002 May 27, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Helsinn Hlthcare AKYNZEO fosnetupitant chloride hydrochloride; palonosetron hydrochloride SOLUTION;INTRAVENOUS 210493-002 May 27, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Helsinn Hlthcare AKYNZEO fosnetupitant chloride hydrochloride; palonosetron hydrochloride SOLUTION;INTRAVENOUS 210493-002 May 27, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Helsinn Hlthcare AKYNZEO fosnetupitant chloride hydrochloride; palonosetron hydrochloride SOLUTION;INTRAVENOUS 210493-002 May 27, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for akynzeo

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 ⤷  Sign Up ⤷  Sign Up
Helsinn Hlthcare AKYNZEO netupitant; palonosetron hydrochloride CAPSULE;ORAL 205718-001 Oct 10, 2014 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for akynzeo

When does loss-of-exclusivity occur for akynzeo?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 8676
Patent: FORMULACIONES INYECTABLES FISIOLÓGICAMENTE BALANCEADAS DE FOSNETUPITANT
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 15323515
Patent: Crystalline forms of an NK-1 antagonist
Estimated Expiration: ⤷  Sign Up

Patent: 17276588
Patent: Physiologically balanced injectable formulations of fosnetupitant
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2018074655
Patent: formulação injetável de fosnetupitant e método de fabricação de uma formulação
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 60599
Patent: FORMES CRISTALLINES D'UN ANTAGONISTE DES RECEPTEURS NK-1 (CRYSTALLINE FORMS OF AN NK-1 ANTAGONIST)
Estimated Expiration: ⤷  Sign Up

Patent: 25837
Patent: FORMULATIONS INJECTABLES PHYSIOLOGIQUEMENT EQUILIBREES DE FOSNETUPITANT (PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT)
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 18003338
Patent: Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
Estimated Expiration: ⤷  Sign Up

China

Patent: 7001275
Patent: NK‑1拮抗剂的晶型 (Crystalline forms of an NK-1 antagonist)
Estimated Expiration: ⤷  Sign Up

Patent: 9310627
Patent: 福奈妥匹坦的生理平衡注射制剂 (Physiologically balanced injectable formulations of fosnetupitant)
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 18011686
Patent: Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0200196
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 22755
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 35980
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 19000169
Patent: FORMULACIONES INYECTABLES FISIOLÓGICAMENTE BALANCEADAS DE FOSNETUPITANT
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 6605
Patent: ФИЗИОЛОГИЧЕСКИ СБАЛАНСИРОВАННЫЙ СОСТАВ ДЛЯ ИНЪЕКЦИЙ, ВКЛЮЧАЮЩИЙ ФОСНЕТУПИТАНТ (PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATION OF FOSNETUPITANT)
Estimated Expiration: ⤷  Sign Up

Patent: 1892837
Patent: ФИЗИОЛОГИЧЕСКИ СБАЛАНСИРОВАННЫЕ СОСТАВЫ ДЛЯ ИНЪЕКЦИЙ, ВКЛЮЧАЮЩИЕ ФОСНЕТУПИТАНТ
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 97871
Patent: FORMES CRYSTALLINES D'UN ANTAGONIST DE NK-1 (CRYSTALLINE FORMS OF AN NK-1 ANTAGONIST)
Estimated Expiration: ⤷  Sign Up

Patent: 35980
Patent: FORMULATIONS INJECTABLES DE FOSNETUPITANT PHYSIOLOGIQUEMENT EQUILIBREES (PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT)
Estimated Expiration: ⤷  Sign Up

Patent: 26231
Patent: FORMULATIONS INJECTABLES DE FOSNETUPITANT PHYSIOLOGIQUEMENT ÉQUILIBRÉES (PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT)
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 3126
Patent: פורמולציות להזרקה של פוסנטופיטנט המאוזנות פיזיולוגית (Physiologically balanced injectable formulations of fosnetupitant)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 36817
Estimated Expiration: ⤷  Sign Up

Patent: 23084
Estimated Expiration: ⤷  Sign Up

Patent: 17529380
Patent: NK−1アンタゴニストの結晶形態
Estimated Expiration: ⤷  Sign Up

Patent: 19521102
Patent: ホスネツピタントの生理学的にバランスのとれた注射可能な製剤
Estimated Expiration: ⤷  Sign Up

Patent: 21183639
Patent: ホスネツピタントの生理学的にバランスのとれた注射可能な製剤 (PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT)
Estimated Expiration: ⤷  Sign Up

Jordan

Patent: 0170137
Patent: صيغ قابلة للحقن متوازنة فسيولوجياً من فوسنيتوبيتانت (Physiologically balanced injectable formulations of fosnetupitant)
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 35980
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 4081
Patent: PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 18015036
Patent: FORMULACIONES INYECTABLES FISIOLOGICAMENTE BALANCEADAS DE FOSNETUPITANT. (PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT.)
Estimated Expiration: ⤷  Sign Up

Moldova, Republic of

Patent: 35980
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 513
Patent: Formulations injectables de fosnetupitant physiologiquement equilibrees
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 190347
Patent: FORMULACIONES INYECTABLES FISIOLOGICAMENTE BALANCEADAS DE FOSNETUPITANT
Estimated Expiration: ⤷  Sign Up

Philippines

Patent: 018502524
Patent: PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 35980
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 35980
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 852
Patent: FIZIOLOŠKI BALANSIRANE INJEKTABILNE FORMULACIJE FOSNETUPITANTA (PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT)
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201809708P
Patent: PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 35980
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 1807932
Patent: PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2459416
Estimated Expiration: ⤷  Sign Up

Patent: 170063768
Patent: NK-1 길항제의 결정질 형태 (-1 CRYSTALLINE FORMS OF AN NK-1 ANTAGONIST)
Estimated Expiration: ⤷  Sign Up

Patent: 190015276
Patent: 포스네투피탄트의 생리학적으로 균형잡힌 주사가능 제제
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 71226
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 25191
Estimated Expiration: ⤷  Sign Up

Patent: 1613888
Patent: Crystalline forms of an NK-1 antagonist
Estimated Expiration: ⤷  Sign Up

Patent: 1801727
Patent: Physiologically balanced injectable formulations of fosnetupitant
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 2285
Patent: ФІЗІОЛОГІЧНО ЗБАЛАНСОВАНІ СКЛАДИ ДЛЯ ІН'ЄКЦІЙ, ЯКІ ВКЛЮЧАЮТЬ ФОСНЕТУПІТАНТ (PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT)
Estimated Expiration: ⤷  Sign Up

Uruguay

Patent: 273
Patent: FORMULACIONES INYECTABLES FISIOLÓGICAMENTE BALANCEADAS DE FOSNETUPITANT
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering akynzeo around the world.

Country Patent Number Title Estimated Expiration
Mexico 2018015036 FORMULACIONES INYECTABLES FISIOLOGICAMENTE BALANCEADAS DE FOSNETUPITANT. (PHYSIOLOGICALLY BALANCED INJECTABLE FORMULATIONS OF FOSNETUPITANT.) ⤷  Sign Up
Ireland 68434 New tricyclic compounds ⤷  Sign Up
European Patent Office 2727590 Compositions pour traiter les nausées et vomissements à médiation centrale (Compositions for treating centrally mediated nausea and vomiting) ⤷  Sign Up
Australia 6696390 ⤷  Sign Up
Ukraine 105817 КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ТОШНОТЫ И РВОТЫ ЦЕНТРАЛЬНОГО ПРОИСХОЖДЕНИЯ;КОМПОЗИЦІЇ ДЛЯ ЛІКУВАННЯ НУДОТИ І БЛЮВАННЯ ЦЕНТРАЛЬНОГО ПОХОДЖЕННЯ (Normal;heading 1;heading 2;heading 3;COMPOSITIONS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for akynzeo

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2785706 2090015-5 Sweden ⤷  Sign Up PRODUCT NAME: FOSNETUPITANT; REG. NO/DATE: EU/1/15/1001 20200317
2785706 CA 2020 00028 Denmark ⤷  Sign Up PRODUCT NAME: FOSNETUPITANT OG FARMACEUTISK ACCEPTABLE SALTE ELLER SOLVATER HERAF, SAERLLIGT FOSNETUPITANT KLORID HYDROKLORID; REG. NO/DATE: EU/1/15/1001 20200318
1035115 CA 2015 00044 Denmark ⤷  Sign Up PRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150527
1035115 C01035115/01 Switzerland ⤷  Sign Up PRODUCT NAME: NETUPITANT; REGISTRATION NO/DATE: SWISSMEDIC 65499 06.11.2015
2785706 2020030 Norway ⤷  Sign Up PRODUCT NAME: FOSNETUPITANT OG FARMASOEYTISK AKSEPTABLE SALTER OG SOLVATER DERAV SPESIELT FOSNETUPITANT KLORID HYDROKLORID; REG. NO/DATE: EU/1/15/1001 20200318
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.